secwatch.observer — SEC 8-K summary
======================================

Issuer:     AIM ImmunoTech Inc. (AIM)
CIK:        0000946644
Form:       8-K
Filed at:   2026-08-10T12:40:31+00:00
Accession:  0001493152-26-036753
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02
LLM model:  deepseek-v4-flash:cloud@v2

AIM ImmunoTech reports Q2 2026 net loss of $3.8M; completes Phase 2 pancreatic cancer enrollment
--------------------------------------------------------------------------------

- Q2 2026 net loss of $3.8M ($0.43/share) vs $2.8M ($3.68/share) in Q2 2025; cash $9.9M vs $3.0M at year-end 2025.
- Completed enrollment and Ampligen dosing in Phase 2 DURIPANC trial (metastatic pancreatic cancer) with AstraZeneca's Imfinzi.
- Engaged Thermo Fisher's PPD for Phase 3 study design; anticipates DURIPANC clinical benefit data Q1 2027, OS data Q3 2027.
- Ampligen showed median OS 34.8 months vs 12.5 months historical controls in Dutch Named Patient Program.
- Regained full compliance with NYSE American listing standards; planning Ebola virus disease initiatives.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/946644/000149315226036753/0001493152-26-036753-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/946644/000149315226036753/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-036753

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer